688276.SH
百克生物
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 16.22
−6.57%Year over year
Reported trailing growth
- Revenue
- -47.4%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +51.1%
- Operating cash flow
- -7.8%
Forward estimates
Based on analyst estimates
- Revenue
- +127.5%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -17.3%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -29.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026